Global Tech Times: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Global Tech Times.

December 2025

Mo	Tu	We	Th	Fr	Sa	Su
1	2	3	4	5	6	7
8	9	10	11	12	13	14
15	16	17	18	19	20	21
22	23	24	25	26	27	28
29	30	31

January 2026

Mo	Tu	We	Th	Fr	Sa	Su
			1	2	3	4
5	6	7	8	9	10	11
12	13	14	15	16	17	18
19	20	21	22	23	24	25
26	27	28	29	30	31

February 2026

Mo	Tu	We	Th	Fr	Sa	Su
						1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28

Press releases published on December 7, 2025

Dec. 7, 2025

GoHighLevel SaaS Mode: New Guide Uncovers the Most Profitable Agency Model of 2026

EIN Presswire

Dec. 7, 2025

Same Day Garage Door, LLC Introduces Garage Door Replacement Program to Support Lima, OH Homes During Peak Winter Season

EIN Presswire

Dec. 7, 2025

Leading Edge Network Announces 30 New Shows Launching January 2026 on DX Virtual TV

EIN Presswire

Dec. 7, 2025

Smart Building Market Poised to Surpass $247.17 Billion by 2032 | Growing at 12.3% CAGR

EIN Presswire

Dec. 7, 2025

Inferenz and Caregence Announce Strategic Merger to Redefine AI Innovation in Healthcare

EIN Presswire

$At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-in-Class Therapy for relapsed/refractory AL Amyloidosis$

Dec. 7, 2025

At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-in-Class Therapy for relapsed/refractory AL Amyloidosis

GlobeNewswire

Dec. 7, 2025

ImCheck Reports Durable Responses and Early Overall Survival Signal with ICT01 in First-line AML at ASH 2025

GlobeNewswire

Dec. 7, 2025

Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and Exposition

GlobeNewswire

Dec. 7, 2025

Lynozyfic™ (linvoseltamab) Monotherapy in Newly Diagnosed Multiple Myeloma (NDMM) Shows Impressive Responses, Supporting Rationale as a Potential Foundation in Frontline Treatment

GlobeNewswire

Dec. 7, 2025

Dyne Therapeutics to Host Investor Conference Call and Webcast to Review Topline Results from Registrational Expansion Cohort (REC) of DELIVER Clinical Trial of Z-Rostudirsen (DYNE-251) in Duchenne Muscular Dystrophy; Tomorrow, December 8 at 8:00 a.m. ET

GlobeNewswire

Dec. 7, 2025

ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual Meeting

GlobeNewswire

Dec. 7, 2025

Molecular Partners Presents Updated Data from Ongoing Phase 1/2a Trial of MP0533 in AML at ASH Annual Meeting

GlobeNewswire